Abstract
The RAF-MEK and PI3K-AKT pathways are both frequently deregulated in cancer, and often play a critical role in oncogenesis. In the previous years, major progress has been made in the development of targeted drugs against signaling kinases which are involved in carcinogenesis. Currently, targeted drugs against RAF, MEK, PI3K and AKT (among several others) have entered clinical investigation. Here we describe tumor causing mutations of these kinases, as well as the small molecule inhibitors that target these kinases, which contributes to improved ways of treating human cancer.
Keywords: AKT, Antitumor activity, Inhibitors, MEK, PI3K, RAF, Targeted drugs
Current Cancer Therapy Reviews
Title:Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Volume: 8 Issue: 3
Author(s): Lobke G.M. Cremers and Johannes Boonstra
Affiliation:
Keywords: AKT, Antitumor activity, Inhibitors, MEK, PI3K, RAF, Targeted drugs
Abstract: The RAF-MEK and PI3K-AKT pathways are both frequently deregulated in cancer, and often play a critical role in oncogenesis. In the previous years, major progress has been made in the development of targeted drugs against signaling kinases which are involved in carcinogenesis. Currently, targeted drugs against RAF, MEK, PI3K and AKT (among several others) have entered clinical investigation. Here we describe tumor causing mutations of these kinases, as well as the small molecule inhibitors that target these kinases, which contributes to improved ways of treating human cancer.
Export Options
About this article
Cite this article as:
G.M. Cremers Lobke and Boonstra Johannes, Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment, Current Cancer Therapy Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339412802653209
DOI https://dx.doi.org/10.2174/157339412802653209 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Four-Component Synthesis of 1,2-Dihydropyridine Derivatives and their Evaluation as Anticancer Agents
Medicinal Chemistry Daphnane-Type Diterpene Orthoesters and their Biological Activities
Mini-Reviews in Medicinal Chemistry Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Journey of 2′-deoxy-2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent
Current Medicinal Chemistry Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Agaricus blazei Water Extracts as Alternative Medicines
Current Pharmaceutical Analysis Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Open Architecture PCR-Based Methods for Differential Gene Expression Analysis
Current Pharmaceutical Analysis Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Current Drug Targets Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets Application of Bacterial Nanocellulose in Cancer Drug Delivery: A Review
Current Pharmaceutical Design Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research Quality Survival with Advanced Cervical Cancer
Current Women`s Health Reviews Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents